Please ensure Javascript is enabled for purposes of website accessibility

Why Has Pfizer Stock Floundered?

By Keith Speights and Brian Orelli, PhD - Feb 23, 2021 at 8:15AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There are two main reasons. At least one of them, though, isn't a problem anymore.

Last year, the major market indexes skyrocketed. But not Pfizer (PFE 1.55%). The big pharma stock actually fell slightly. And the downtrend has continued into this year. In this Motley Fool Live video, recorded on Feb. 17, contributors Keith Speights and Brian Orelli answer a viewer's question about why Pfizer stock has floundered.

Keith Speights: Ben asked the question, "Why is it that Pfizer," ticker there is PFE, "Why is it that Pfizer is down?" I have not looked at Pfizer stock this morning Let's see what's going on.

Brian Orelli: Maybe he's talking about for the last year and a half. [laughs] It has not done anything.

Speights: It's actually up a little this morning, but OK.

Orelli: [laughs] Ben maybe asking about the general in why isn't it responding to the COVID--

Speights: I think I could field that question, Brian, and you joined in, but yeah. [laughs] There are a couple of reasons Pfizer has been down, let's say, like you say, Brian, over the last year or two.

One of the big reasons is that Pfizer has been just weighed down by their legacy drugs, Lyrica, other drugs that have lost patent exclusivity, and it's really just weighed on their revenue growth, earnings growth, and that's been a big problem. That's not an issue for Pfizer anymore though because they spun off that business, the Upjohn unit and merged it with Mylan last year, and so that's not an issue for Pfizer going forward.

Another reason Pfizer has been down is that they've had some clinical setbacks. They really had high hopes for breast cancer drug Ibrance, and early breast cancer setting, and had a couple of clinical studies that didn't pan out so well, and so that's been another negative impact on the stock.

But for the long term for Pfizer, I think it looks better than it's looking quite a while now. They've got their COVID vaccine, like I said, the Upjohn unit that's no longer part of Pfizer. They've got some other drugs that are generating fast growth. I think that's why Pfizer was down, but I think Pfizer is in much better position to move higher now. What do you think, Brian?

Orelli: The Upjohn, if I'm remembering correctly, I'm not a Pfizer shareholder, the Upjohn unit's investors got shares of that Upjohn unit. Is that correct?

Speights: That's right. Pfizer shareholders got shares.

Orelli: Of their new company.

Speights: VTRS. I don't know how they pronounce it. I'm assuming is Viatris (VTRS 1.06%) so if I'm getting that wrong, I'm sorry. Ticker there's VTRS but yeah, Pfizer shareholders did get shares in the new company.

Orelli: Yeah. So you have to factor that in when you're looking at Pfizer charts, but that valuation went away from the valuation of Pfizer's stock.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
$54.55 (1.55%) $0.83
Viatris Inc. Stock Quote
Viatris Inc.
$11.96 (1.06%) $0.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.